With more than 70 million patients worldwide, epilepsy is the most prevalent severe neurological disorder. In addition to the recurrent seizures that characterize epilepsy, patients also suffer from cognitive, behavioral and psychological comorbidities. The social and economic consequences of epilepsy are huge, with an estimate cost equivalent to 0.2% of GDP in developed countries (i.e. €40 billion per year in Europe), and even more in developing countries.
One third of patients with epilepsy is refractory to currently available treatments and almost half of patients suffers from side effects, such as lowered cognitive performances. Furthermore, the anti-epileptic drugs currently available on the market aim to limit the seizures but leave unattended all the other disorders due to the disease, which truly degrade the patients’ quality of life.
Thanks to the new mechanisms of action of its drug candidates, GAOMA Therapeutics aspire to globally address epilepsy, both on seizures and cognition aspects of the disease.
Due to the pharmacological properties of its drug candidates, GAOMA Therapeutics aims to explore the potential benefits of these molecules in other indications than epilepsy, both in the fields of neurological and non-neurological disorders.
Alzheimer Disease (AD)
Today, approximately 50 million people worldwide live with AD or a related form of dementia. AD is a growing challenge for the coming decades because of the increasing aged population and the today lack of efficient pharmaceutical treatment.